Executive Summary
Gland Pharma Ltd reported Q3FY26 revenues of ₹1,695 crore, up 22.47% YoY, with consolidated net profit rising 27.32% to ₹261 crore. Total expenses increased 20.03% YoY to ₹1,372 crore, reflecting strong revenue growth with controlled cost escalation.
Revenue & Growth
Revenues grew to ₹1,695.00 crore in Q3FY26 from ₹1,384.00 crore YoY, marking 22.47% expansion. Total expenses rose 20.03% YoY to ₹1,372.00 crore, maintaining favorable operating leverage.
Profitability & Margins
Consolidated net profit increased 27.32% YoY to ₹261.00 crore from ₹205.00 crore. Basic EPS rose 27.78% to ₹15.87 from ₹12.42.
Balance-Sheet Highlights
The dataset lacks detailed balance sheet items such as assets, liabilities, equity, net debt, or current ratio for Q3FY26.
Cash Flow / Liquidity
Operating cash flow, free cash flow, and liquidity metrics are not specified in the Q3FY26 dataset.
Key Ratios / Metrics
Gross, EBITDA, and PAT margins are unavailable. Net debt/EBITDA cannot be computed without debt and EBITDA figures. QoQ changes for revenue, EBITDA, and PAT are not provided.
